- Home
- IAUX vs ATAI Comparison
IAUX vs ATAI Comparison
Compare IAUX & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IAUX | ATAI |
|---|---|---|
| Founded | 2020 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 2.7B |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | IAUX | ATAI |
|---|---|---|
| Price | $1.81 | $7.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $1.50 | ★ $15.88 |
| AVG Volume (30 Days) | ★ 10.4M | 8.6M |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.76 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $95,193,000.00 | $4,089,000.00 |
| Revenue This Year | $132.25 | N/A |
| Revenue Next Year | $89.76 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 89.12 | ★ 1227.60 |
| 52 Week Low | $0.74 | $3.27 |
| 52 Week High | $2.24 | $7.45 |
Technical Indicators
Market Signals| Indicator | IAUX | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 66.14 | 75.74 |
| Support Level | $1.79 | $3.89 |
| Resistance Level | $1.95 | N/A |
| Average True Range (ATR) | 0.07 | 0.05 |
| MACD | 0.02 | -0.07 |
| Stochastic Oscillator | 90.82 | 87.93 |
Price Performance
Historical ComparisonAbout IAUX i-80 Gold Corp.
i-80 Gold Corp is a well-financed gold and silver producer engaged in the exploration, development, and production of gold, silver, and poly-metallic deposits. The Company's principal assets include the Ruby Hill Mine, Lone Tree Mine, Granite Creek Mine, and McCoy-Cove Project.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.